These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 26196746)

  • 21. All-trans retinoic acid enhances gemcitabine cytotoxicity in human pancreatic cancer cell line AsPC-1 by up-regulating protein expression of deoxycytidine kinase.
    Kuroda H; Tachikawa M; Uchida Y; Inoue K; Ohtsuka H; Ohtsuki S; Unno M; Terasaki T
    Eur J Pharm Sci; 2017 May; 103():116-121. PubMed ID: 28215943
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship between single nucleotide polymorphisms in the deoxycytidine kinase gene and chemosensitivity of gemcitabine in six pancreatic cancer cell lines.
    Si S; Liao Q; Zhao YP; Hu Y; Zhang Q; You LL
    Chin Med J (Engl); 2011 Feb; 124(3):419-22. PubMed ID: 21362344
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells.
    Nakano Y; Tanno S; Koizumi K; Nishikawa T; Nakamura K; Minoguchi M; Izawa T; Mizukami Y; Okumura T; Kohgo Y
    Br J Cancer; 2007 Feb; 96(3):457-63. PubMed ID: 17224927
    [TBL] [Abstract][Full Text] [Related]  

  • 24. dCK negatively regulates the NRF2/ARE axis and ROS production in pancreatic cancer.
    Hu Q; Qin Y; Xiang J; Liu W; Xu W; Sun Q; Ji S; Liu J; Zhang Z; Ni Q; Xu J; Yu X; Zhang B
    Cell Prolif; 2018 Aug; 51(4):e12456. PubMed ID: 29701272
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity.
    Kroep JR; Loves WJ; van der Wilt CL; Alvarez E; Talianidis I; Boven E; Braakhuis BJ; van Groeningen CJ; Pinedo HM; Peters GJ
    Mol Cancer Ther; 2002 Apr; 1(6):371-6. PubMed ID: 12477049
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phosphorylation of deoxycytidine kinase on Ser-74: impact on kinetic properties and nucleoside analog activation in cancer cells.
    Amsailale R; Van Den Neste E; Arts A; Starczewska E; Bontemps F; Smal C
    Biochem Pharmacol; 2012 Jul; 84(1):43-51. PubMed ID: 22490700
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clofarabine exerts antileukemic activity against cytarabine-resistant B-cell precursor acute lymphoblastic leukemia with low deoxycytidine kinase expression.
    Huang M; Inukai T; Miyake K; Tanaka Y; Kagami K; Abe M; Goto H; Minegishi M; Iwamoto S; Sugihara E; Watanabe A; Somazu S; Shinohara T; Oshiro H; Akahane K; Goi K; Sugita K
    Cancer Med; 2018 Apr; 7(4):1297-1316. PubMed ID: 29473342
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Attenuation of phosphorylation by deoxycytidine kinase is key to acquired gemcitabine resistance in a pancreatic cancer cell line: targeted proteomic and metabolomic analyses in PK9 cells.
    Ohmine K; Kawaguchi K; Ohtsuki S; Motoi F; Egawa S; Unno M; Terasaki T
    Pharm Res; 2012 Jul; 29(7):2006-16. PubMed ID: 22419259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CYR61/CCN1 Regulates dCK and CTGF and Causes Gemcitabine-resistant Phenotype in Pancreatic Ductal Adenocarcinoma.
    Maity G; Ghosh A; Gupta V; Haque I; Sarkar S; Das A; Dhar K; Bhavanasi S; Gunewardena SS; Von Hoff DD; Mallik S; Kambhampati S; Banerjee SK; Banerjee S
    Mol Cancer Ther; 2019 Apr; 18(4):788-800. PubMed ID: 30787177
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Danggui Buxue Decoction Sensitizes the Response of Non-Small-Cell Lung Cancer to Gemcitabine via Regulating Deoxycytidine Kinase and P-glycoprotein.
    Sun X; Xu X; Chen Y; Guan R; Cheng T; Wang Y; Jin R; Song M; Hang T
    Molecules; 2019 May; 24(10):. PubMed ID: 31130654
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paclitaxel alters the expression and specific activity of deoxycytidine kinase and cytidine deaminase in non-small cell lung cancer cell lines.
    Shord SS; Patel SR
    J Exp Clin Cancer Res; 2009 Jun; 28(1):76. PubMed ID: 19500405
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ribonucleotide reductase subunit M1 is a possible chemoresistance marker to gemcitabine in biliary tract carcinoma.
    Ohtaka K; Kohya N; Sato K; Kitajima Y; Ide T; Mitsuno M; Miyazaki K
    Oncol Rep; 2008 Aug; 20(2):279-86. PubMed ID: 18636187
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines.
    Giovannetti E; Mey V; Danesi R; Mosca I; Del Tacca M
    Clin Cancer Res; 2004 May; 10(9):2936-43. PubMed ID: 15131028
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.
    Klanova M; Lorkova L; Vit O; Maswabi B; Molinsky J; Pospisilova J; Vockova P; Mavis C; Lateckova L; Kulvait V; Vejmelkova D; Jaksa R; Hernandez F; Trneny M; Vokurka M; Petrak J; Klener P
    Mol Cancer; 2014 Jun; 13():159. PubMed ID: 24972933
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting Casein Kinase 1 Delta Sensitizes Pancreatic and Bladder Cancer Cells to Gemcitabine Treatment by Upregulating Deoxycytidine Kinase.
    Vena F; Bayle S; Nieto A; Quereda V; Aceti M; Frydman SM; Sansil SS; Grant W; Monastyrskyi A; McDonald P; Roush WR; Teng M; Duckett D
    Mol Cancer Ther; 2020 Aug; 19(8):1623-1635. PubMed ID: 32430484
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Deoxycytidine Kinase (DCK) Mutations in Human Acute Myeloid Leukemia Resistant to Cytarabine.
    Wu B; Mao ZJ; Wang Z; Wu P; Huang H; Zhao W; Zhang L; Zhang Z; Yin H; Gale RP; Yin B
    Acta Haematol; 2021; 144(5):534-541. PubMed ID: 33626530
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potent Sensitisation of Cancer Cells to Anticancer Drugs by a Quadruple Mutant of the Human Deoxycytidine Kinase.
    Coulibaly ST; Rossolillo P; Winter F; Kretzschmar FK; Brayé M; Martin DP; Lener D; Negroni M
    PLoS One; 2015; 10(10):e0140741. PubMed ID: 26485161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 trial.
    McAllister F; Pineda DM; Jimbo M; Lal S; Burkhart RA; Moughan J; Winter KA; Abdelmohsen K; Gorospe M; Acosta Ade J; Lankapalli RH; Winter JM; Yeo CJ; Witkiewicz AK; Iacobuzio-Donahue CA; Laheru D; Brody JR
    Cancer Biol Ther; 2014 Jun; 15(6):688-98. PubMed ID: 24618665
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas.
    Pignochino Y; Sarotto I; Peraldo-Neia C; Penachioni JY; Cavalloni G; Migliardi G; Casorzo L; Chiorino G; Risio M; Bardelli A; Aglietta M; Leone F
    BMC Cancer; 2010 Nov; 10():631. PubMed ID: 21087480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of deoxycytidine kinase (dCK) activity in gemcitabine's radioenhancement in mice and human cell lines in vitro.
    Grégoire V; Rosier JF; De Bast M; Bruniaux M; De Coster B; Octave-Prignot M; Scalliet P
    Radiother Oncol; 2002 Jun; 63(3):329-38. PubMed ID: 12142097
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.